MPO and acute lymphoblastic leukemia: According to the classification of the World Health Organization (WHO, 2008), AML can be evaluated and differentiated from ALL using flow cytometry (FCM)/immunohistochemistry (IHC)/cytochemistry techniques, with myeloperoxidase (MPO) being one of the clear markers for differentiation (47).